Modulating anti-HIV immunity by plasmacytoid dendritic cells
Modulating anti-HIV immunity by plasmacytoid dendritic cells
批准号:
8240408
负责人:
Nina Bhardwaj
金额:
$41.83万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-15 至 2013-03-31
关键词:
AcuteAdenosineAntigen PresentationAntiviral AgentsAntiviral ResponseAttenuatedBloodCD4 Positive T LymphocytesCell MaturationCellsChronic PhaseCyclic AMPDataDendritic CellsDendritic cell activationDevelopmentDioxygenasesDiseaseDisease ProgressionEndocytosisEnzymesEventGenerationsGenomicsGranzymeHIVHIV AntigensHIV InfectionsHIV-1HumanIL2RA geneITGAX geneImmuneImmune responseImmune systemImmunityIn VitroInfectionInfection ControlInflammatoryInterferon Type IInterleukin-10InterventionKynurenineLaboratoriesLigationLinkLymphoid TissueMeasuresMediatingMediator of activation proteinMetabolic PathwayMyelogenousPathway interactionsPatientsPopulationProcessProductionPropertyRNARegulationRegulatory T-LymphocyteRestRoleSignal PathwaySignal TransductionSmall Interfering RNAStagingT-Cell ProliferationT-LymphocyteTLR7 geneTimeTransforming Growth Factor betaTryptophanUp-RegulationViralViral AntigensVirusVirus Diseasesadaptive immunitycell growthchemokinecytokinecytotoxicimmune activationimprovedin vivoindolamineinhibitor/antagonistknock-downmethyl tryptophanpathogenperforinpreventpublic health relevanceresponseviral RNA
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Human plasmacytoid dendritic cells (pDC) constitute a rare subset of blood dendritic cells (DC), distinct from myeloid CD11c+, "conventional" DC (cDC). Through production of high levels of type I IFN in response to virus infection, pDC serve as a critical link between innate and adaptive antiviral immune responses. Recent observations from my laboratory have highlighted their particular role in the immune regulation of HIV-1 infection. pDCs, but not cDCs, undergo activation following CD4 mediated endocytosis of HIV-1 and subsequent activation of TLR7 with genomic RNA. Activated pDCs upregulate costimulatory molecules, produce pro-inflammatory cytokines and chemokines and activate immature cDCs in a bystander fashion. As a counterpoint to the induction of these anti-viral responses, HIV-activated pDCs simultaneously induce the differentiation of Tregulatory cells (Tregs) from naive resting CD4+ T cells, in a TLR7 dependent manner. Treg generation requires the expression of indolamine 2,3-dioxygenase (IDO), an enzyme that catabolizes tryptophan to kynurenine, as it is reversed upon addition of the specific inhibitor 1 methyl-tryptophan. The T regs generated ("inducible T regs") inhibit the proliferation of activated T cells and maturation of cDC, thereby attenuating the induction of ongoing adaptive immune responses. Thus pDCs inhibit viral replication and promote anti-viral immunity, but at the same time limit the extent of immune activation. This newly ascribed property of pDCs is especially relevant in HIV infection where control of excessive immune activation could be essential to prevent virus dissemination and progression of disease. In this application we propose to: (1) Identify the mechanism(s) underlying HIV-dependent, pDC-induced T reg differentiation, focusing in particular on IDO; (2) Determine the regulatory processes used by Tregs to inhibit T cell growth and cDC activation; (3) Establish the in vivo relevance of pDC-mediated induction of Treg in HIV-infected patients. These studies will greatly improve our understanding of the events that follow pDC activation by HIV and potentially result in clinically applicable approaches to enhance anti-HIV immune responses in vivo.
PUBLIC HEALTH RELEVANCE: These studies will investigate the mechanisms used by the HIV virus to evade the immune system. Specifically, we will explore how HIV induces the generation of T cells which have suppressive qualities and block the development of several beneficial anti-viral responses. By understanding how these suppressive T cells are generated we can devise strategies to modulate their function and promote anti-viral immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
-
批准号:10434380
-
项目类别:
-
资助金额:$5.4万
-
财政年份:2022
-
负责人:Nina Bhardwaj
-
依托单位:
The Tisch Cancer Institute (TCI) Paul Calabresi K12 Career Development Award for Clinical Oncology
-
批准号:10623252
-
项目类别:
-
资助金额:$56.69万
-
财政年份:2022
-
负责人:Nina Bhardwaj
-
依托单位:
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
-
批准号:10652272
-
项目类别:
-
资助金额:$68.93万
-
财政年份:2020
-
负责人:Nina Bhardwaj
-
依托单位:
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer
-
批准号:10380068
-
项目类别:
-
资助金额:$68.93万
-
财政年份:2020
-
负责人:Nina Bhardwaj
-
依托单位:
Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy
-
批准号:10203557
-
项目类别:
-
资助金额:$16.84万
-
财政年份:2020
-
负责人:Nina Bhardwaj
-
依托单位:
NK cell exhaustion in metastatic melanoma
-
批准号:9177359
-
项目类别:
-
资助金额:$40.36万
-
财政年份:2016
-
负责人:Nina Bhardwaj
-
依托单位:
Cancer Immunology
-
批准号:10454170
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2015
-
负责人:Nina Bhardwaj
-
依托单位:
Cancer Immunology (CI) (Project-001)
-
批准号:8932191
-
项目类别:
-
资助金额:$0.93万
-
财政年份:2015
-
负责人:Nina Bhardwaj
-
依托单位:
Cancer Immunology
-
批准号:10674510
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2015
-
负责人:Nina Bhardwaj
-
依托单位:
Cancer Immunology
-
批准号:10022663
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2015
-
负责人:Nina Bhardwaj
-
依托单位:
Matrix metalloproteinase-2 modulates inflammation via TLR2
-
批准号:8777819
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2014
-
负责人:Nina Bhardwaj
-
依托单位:
Matrix metalloproteinase-2 modulates inflammation via TLR2
-
批准号:8874174
-
项目类别:
-
资助金额:$35.17万
-
财政年份:2014
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8744629
-
项目类别:
-
资助金额:$33.86万
-
财政年份:2013
-
负责人:Nina Bhardwaj
-
依托单位:
Induction of Immunity by Non-Replicating HIV-1
-
批准号:8744626
-
项目类别:
-
资助金额:$22.12万
-
财政年份:2013
-
负责人:Nina Bhardwaj
-
依托单位:
NIAID Clinical Trial Planning Grant
-
批准号:8211593
-
项目类别:
-
资助金额:$28.61万
-
财政年份:2011
-
负责人:Nina Bhardwaj
-
依托单位:
Innate Discovery Team
-
批准号:8294657
-
项目类别:
-
资助金额:$120.4万
-
财政年份:2011
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8436297
-
项目类别:
-
资助金额:$39.31万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8058751
-
项目类别:
-
资助金额:$41.83万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
Exposing virus-induced long noncoding RNA in plasmacytoid dendritic cells
-
批准号:10239219
-
项目类别:
-
资助金额:$42.38万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
Modulating anti-HIV immunity by plasmacytoid dendritic cells
-
批准号:8651406
-
项目类别:
-
资助金额:$41.63万
-
财政年份:2010
-
负责人:Nina Bhardwaj
-
依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
-
批准号:82074359
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2020
-
负责人:安晓飞
-
依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
-
批准号:81570244
-
项目类别:面上项目
-
资助金额:57.0万元
-
批准年份:2015
-
负责人:丁兆平
-
依托单位:
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
-
批准号:81171113
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2011
-
负责人:黄文
-
依托单位: